With deep molecular insights from a simple blood sample, Caris Assure™ offers a minimally-invasive liquid biopsy option for biomarker analysis of cancer patients when tissue samples are not available. No matter the specimen type – tissue or blood – Caris Life Sciences’ flexible, multi-faceted molecular profiling platforms deliver uncompromising reliability and performance to guide personalized treatment decisions and help improve patient outcomes.*
Circulating Nucleic Acid Sequencing
Biomarker Analysis (including resistance mutations)
Plasma: cfDNA, cfRNA
White Blood Cells: gDNA, mRNA
Variant Coverage (pathogenic and likely pathogenic)
Tumor-Derived Incidental Germline† Incidental CHIP
Genes & Depth
23,000+ 8,000x (raw average for clinically relevant genes)
Next Generation Sequencing
SNV INDEL CNA Fusions
bTMB HLA Genotype MSI
Two Tubes Whole Blood
Performance in Advanced/Metastatic Patients
Compared to matched tissue collected within 30 days; based on ≥5 ng of cNAS input.
Clinically Actionable SNV and INDEL:
LOD 0.1% VAF
Incidental Germline† :
Caris Assure analyzes 23,000+ genes using whole exome and whole transcriptome sequencing, providing the most robust and accurate assessment of the key molecular features of a patient’s cancer. This comprehensive approach identifies all pan-cancer biomarkers, including a wide range of variant types and genomic signatures.
Caris Assure analyzes both plasma and buffy coat (white blood cell) layers, distinguishing tumor-derived somatic variants from incidental germline† or incidental CHIP variants. The Caris Assure report subtracts incidental CHIP mutations from somatic tumor mutations to reduce false positives and improve assay reliability.
Use our full gene search to verify that it is included in Caris profiling, or browse the list of genes most commonly associated with cancer.
Sign up to receive updates about Caris Assure features and availability.
The online form below is intended for healthcare professionals only. If you are a patient, please contact your doctor for more information about Caris Assure. Not available in all locations.
* Caris Assure is intended for patients with previously diagnosed solid malignant neoplasms where tissue is not available, and is to be used by qualified healthcare professionals. Not available in all locations.
† Not a replacement for comprehensive germline testing. Incidental pathogenic alterations detected in ACMG recognized cancer genes are reported. Negative results do not imply the patient does not harbor a germline mutation.
Place an order today for a comprehensive, personalized Caris profiling report.